Great Bay Bio’s proprietary AlfaCell Fluorescence-Guided Targeted Integration Cell Line Development Platform addresses key limitations of conventional random integration, including lengthy development timelines, labor-intensive clone screening, and unstable expression. It accelerates CMC development and commercialization of complex biologics, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), multispecific antibodies, antibody-drug conjugates (ADCs), and Fc-fusion proteins.

In this article, we address some of the most frequently asked questions in the industry to help you quickly understand the core technical principles and capabilities of the AlfaCell platform.

Q1: What is AlfaCell?

AlfaCell is a fluorescence-based Site-Specific Integration (SSI) cell line development platform independently developed by Great Bay Bio, focused on the rapid development of high-expression, high-stability, and high-quality production cell lines for biologics.

AlfaCell combines SSI technology, fluorescence visual screening technology, and high-throughput analytical technologies such as FACS, VIPS, and Octet to precisely integrate the target gene into a validated, highly active expression region and rapidly screen for stable, high-yield monoclonal cell lines.

Compared with traditional random-integration cell line development, AlfaCell improves development efficiency, reduces expression-variability risk, and accelerates biologics CMC development.

Q2: What is Site-Specific Integration (SSI) cell line development?

SSI is a genetic engineering technology that uses site-specific recombinases to precisely insert the gene of interest into a specific locus of the host cell chromosome. It enables the cell line to achieve: better expression stability; higher batch-to-batch consistency; and lower CMC development risk.

Q3: On which host cell is AlfaCell developed? Does it support CHO cell line development?

AlfaCell is an SSI cell line development platform built on the CHO-K1 (Chinese Hamster Ovary-K1) cell line, dedicated to developing high-expression, high-stability production cell lines for complex biologics such as antibodies, bispecific antibodies, and fusion proteins.

Leveraging the mature industrial foundation of CHO-K1, AlfaCell combines SSI technology, fluorescence visual screening, and high-throughput monoclonal screening to achieve precise target-gene integration and rapid screening of high-potential cell lines.

As one of the most widely used host cells in global commercial biologics manufacturing, CHO-K1 offers: high process maturity; rich scale-up experience; high regulatory acceptance; and applicability to diverse recombinant protein expression.

Based on the CHO-K1 system, AlfaCell can support cell line development for multiple biologic molecule types — including mAbs, bispecific antibodies, multispecific antibodies, ADC-related antibodies, and Fc-fusion proteins — and meets the requirements of downstream CMC development and commercial manufacturing.

Q4: How does AlfaCell achieve precise gene integration?

Based on the CHO-K1 host cell system, AlfaCell employs site-specific recombinase-mediated technology to precisely insert the target gene into a pre-designed genomic locus, achieving stable integration and sustained expression of the exogenous gene.

Compared with traditional random integration, by controlling the insertion position of the target gene, AlfaCell reduces position-effect and expression-variability risks caused by random integration-site heterogeneity, improving the stability and predictability of cell line development.

After precise gene integration, AlfaCell combines fluorescence visual screening, single-cell sorting, and expression analysis to rapidly screen for high-expression, high-stability monoclonal production cell lines.

Q5: How does AlfaCell select the target integration site?

The core of SSI cell line development lies in selecting genomic integration sites with good expression potential and long-term stability, and precisely directing the target gene into that site.

Based on the CHO-K1 host system, AlfaCell systematically evaluates genomic regions and uses AI technology and high-throughput automated screening to identify and validate highly active expression regions as target integration sites with the following characteristics:

• Open chromatin suitable for accommodating long exogenous gene fragments;

• Ability to support long-term genetic stable expression;

• Reduced risk of gene silencing and expression fluctuation.

After the target site is determined, AlfaCell uses site-specific recombinase-mediated technology to precisely insert the expression cassette into the pre-validated high-expression genomic locus, avoiding the uncontrolled insertion-position problem of traditional random integration, which can adversely affect host cell physiology.

Subsequently, fluorescence visual screening, single-cell sorting, and expression analysis are used to perform high-throughput screening of the integrated cells, yielding high-expression, high-stability candidate monoclonal cell lines.

Q6: How does AlfaCell verify whether the target gene is precisely integrated?

AlfaCell confirms candidate cell lines through a multi-dimensional analysis strategy, including:

• Residual fluorescent-marker analysis;

• Gene-integration analysis;

• Monoclonal-origin confirmation;

• Exogenous-gene expression detection;

• Protein-expression-level analysis;

• Stability evaluation.

Combined with fluorescence screening and high-throughput detection technologies, candidate cell lines with development potential can be rapidly identified.

Q7: How does AlfaCell ensure monoclonality?

AlfaCell combines VIPS single-cell sorting technology, monoclonal-origin analysis, and subsequent verification testing to ensure candidate cell lines originate from a single cell clone.

Screening and analysis at the single-cell level reduce the risk of mixed clones and provide assurance for subsequent stable expression and production consistency.

Q8: What are the advantages of AlfaCell's fluorescence screening technology?

AlfaCell combines fluorescence technology with SSI technology, enabling rapid observation of target-gene integration and expression status.

Combined with:

• FACS flow sorting;

• VIPS single-cell imaging sorting;

• Octet protein-expression detection;

it can rapidly identify:

• High-expression clones;

• Monoclonal-origin cells;

• Candidate cell lines with industrial production potential.

This approach reduces the blindness of traditional screening workflows and improves development efficiency.

Q9: Why does SSI improve the predictability of cell line development compared with random integration?

During random integration, the exogenous gene may randomly enter different genomic regions, and different insertion positions may lead to:

• High host-cell physiological uncertainty;

• Expression-level variation;

• Gene silencing;

• Declining cell line stability.

By controlling the target-gene insertion position, SSI standardizes the development process across different projects and improves the predictability of cell line performance.

For commercial biologics manufacturing, a stable and controllable integration method helps reduce downstream CMC development risk and improve process scale-up and production consistency.

Q10: What is the difference between AlfaCell SSI cell lines and traditional random-integration CHO cell lines?

Traditional random-integration CHO cell line development typically requires screening high-expression clones from a large pool of randomly integrated clones, with problems such as long timelines, high screening costs, and uncertain outcomes.

AlfaCell adopts an SSI strategy, directing the target gene into a stable, high-expression region and combining fluorescence-assisted screening to rapidly obtain high-potential clones. Key advantages include:

• High controllability of host cell physiology;

• Genomic stability;

• More controllable integration sites;

• More stable expression performance;

• Reduced large-scale blind screening;

• Shortened cell line development cycle.

Q11: During cell line development, why is AlfaCell's development cycle shorter than traditional CHO cell line development?

Traditional CHO cell line development usually relies on random integration and extensive clone screening, requiring the search for high-expression clones among a large candidate pool, resulting in a longer development cycle.

Based on the CHO-K1 SSI cell line platform, AlfaCell uses site-specific recombinase-mediated precise gene integration to direct the target gene into predefined sites, and combines fluorescence visual screening, single-cell sorting, and high-throughput analysis to improve candidate-clone screening efficiency.

By reducing ineffective work in random screening, AlfaCell can significantly shorten the cell line development cycle; public cases show the fastest RCB (Research Cell Bank) construction in about 1.5 months.

Q12: Why are SSI cell lines more suitable for industrial biologics manufacturing?

Industrial manufacturing requires cell lines with long-term stable expression capability and batch-to-batch consistency.

By reducing the position effect caused by random insertion, SSI gives cell lines better stability and predictability during:

• Host-cell physiological control;

• Genomic stability;

• Long-term passage;

• Process scale-up;

• Production batch changeover.

Therefore, SSI has become an important technology direction for the development of next-generation high-quality production cell lines.

Q13: Can cell lines developed with AlfaCell undergo long-term stability studies?

Yes.

Based on SSI technology, by controlling the target-gene insertion position, AlfaCell reduces the expression-fluctuation and gene-silencing risks caused by insertion-site differences in traditional random integration, improving the predictability of long-term stable expression from the source.

During cell line development, AlfaCell performs long-term stability assessment of candidate cell lines through stability evaluation, expression-level analysis, and continuous passage observation.

By monitoring the cell line during continuous culture — including:

• Expression maintenance capability;

• Cell growth characteristics;

• Product quality attribute changes;

AlfaCell evaluates the cell line's long-term production potential, providing data support for downstream CMC development, process scale-up, and commercial manufacturing.

Q14: Do cell lines developed with AlfaCell require long-term drug pressure?

No.

Compared with other cell line construction methods (which require long-term drug selective pressure to maintain the stability of the integrated exogenous gene), AlfaCell-built cell lines are selected for the integrated gene using only 48 hours of hygromycin pressure during the transfection stage. After sorting into plates and expansion to the RCB stage, no further drug pressure is needed. The AlfaCell-derived RCB can be used directly to establish the Master Cell Bank (MCB).

Q15: Can AlfaCell reduce CMC development risk?

Yes.

Through SSI, stable-expression screening, and early quality analysis, AlfaCell can help customers:

• Assess expression potential earlier;

• Reduce cell-line instability risk;

• Identify development issues sooner.